Aigen Investment Management LP Acquires Shares of 11,753 Fulgent Genetics, Inc. (NASDAQ:FLGT)

Aigen Investment Management LP bought a new position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 11,753 shares of the company’s stock, valued at approximately $217,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in Fulgent Genetics by 113.2% in the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock worth $7,346,000 after acquiring an additional 179,477 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Fulgent Genetics by 220.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 43,813 shares of the company’s stock worth $952,000 after purchasing an additional 30,160 shares during the last quarter. State Street Corp lifted its stake in Fulgent Genetics by 1.4% in the third quarter. State Street Corp now owns 793,545 shares of the company’s stock valued at $17,244,000 after purchasing an additional 10,868 shares during the last quarter. Franklin Resources Inc. purchased a new position in Fulgent Genetics in the third quarter valued at approximately $215,000. Finally, Geode Capital Management LLC grew its holdings in Fulgent Genetics by 2.7% during the third quarter. Geode Capital Management LLC now owns 502,869 shares of the company’s stock valued at $10,930,000 after purchasing an additional 13,320 shares during the period. 48.06% of the stock is owned by hedge funds and other institutional investors.

Fulgent Genetics Trading Up 3.9 %

FLGT opened at $18.59 on Monday. Fulgent Genetics, Inc. has a 12 month low of $14.57 and a 12 month high of $25.11. The company has a market cap of $573.11 million, a PE ratio of -3.37 and a beta of 1.54. The company has a 50 day moving average of $17.14 and a 200 day moving average of $19.20.

Insiders Place Their Bets

In other news, CFO Paul Kim purchased 100,000 shares of the stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average cost of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the acquisition, the chief financial officer now owns 348,282 shares in the company, valued at $5,558,580.72. This represents a 40.28 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 31.76% of the company’s stock.

Wall Street Analyst Weigh In

FLGT has been the topic of several research reports. Piper Sandler lowered their target price on Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. StockNews.com upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 5th.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.